Articles tagged with Alzheimer Disease
Researchers have identified a new protein called 'aggregatin' that accumulates in brain plaques and may be linked to Alzheimer's disease progression. Suppressing this protein could lead to future treatments aimed at slowing the disease's advance.
A recent study found that community-dwellers with Alzheimer's disease who used antipsychotics had a 29% higher risk of head injuries and a 22% higher risk of traumatic brain injuries. The risk was highest when antipsychotics were first introduced.
Scientists discovered a key mechanism underlying Alzheimer's pathology, revealing how amyloid-beta oligomers hijack norepinephrine signaling to activate GSK3-beta and hyper-phosphorylate tau protein. This rewiring of the alpha-2A adrenergic receptor may explain the failure of previous clinical trials targeting amyloid protein buildup.
Researchers have developed a new small molecule that potentiates synaptic NMDA receptors, restoring brain rhythms to normal patterns and improving memory in mouse models of Alzheimer's disease and Dravet syndrome. The treatment also reduced abnormal brain activity associated with these conditions.
A protein associated with ovarian cancer may contribute to the progression of Alzheimer's disease by impairing mitochondria function and causing neuronal damage. Researchers have identified OCIAD1 as a potential therapeutic target for the disease.
A study by Uppsala University found that sleeping deprivation for just one night increased tau protein levels in the blood of young, healthy men. This accumulation can start decades before Alzheimer's symptoms appear.
The University of Arizona Center for Innovation in Brain Science has received a $1.6 million grant to apply big data analytics and computational modeling to better understand Alzheimer's disease. The project aims to identify patient-specific therapeutic targets and evaluate the effectiveness and safety of drug combinations.
A nationwide Finnish study found that individuals with Alzheimer's disease who took antipsychotic medications had a 29% higher risk of head injuries compared to those who didn't. This is particularly concerning as these patients already have a higher risk of falling and traumatic brain injuries.
Scientists developed a new screening platform that identified a set of drug-like compounds, including an ingredient in sore throat lozenges, capable of protecting brain cells' mitochondria from damage. The findings provide hope for developing new treatments for neurodegenerative diseases like Alzheimer's and ALS.
A clinical trial is underway to develop a cost-effective biomarker panel that can identify people in the earliest stages of Alzheimer's disease. The study uses retinal screening processes and aims to create a gold standard reference database for early detection.
A new study finds that tau protein is a more reliable predictor of brain atrophy in Alzheimer's patients than amyloid plaques. Tau PET imaging technology has the potential to accelerate clinical trials and improve individualized patient care.
Researchers have successfully tested a new immunotherapy approach that targets brain plaque and tau protein aggregates linked to Alzheimer's disease. The treatment, developed using a combination of vaccines, shows promise for preventing dementia in humans within two years.
A Hebrew University research team has discovered a potential link between the BCG vaccine and reduced Alzheimer's disease risk in cancer patients. The study found that those who received the BCG vaccine had significantly lower rates of developing Alzheimer's compared to those who did not.
A new study by McGill University researchers found that APOEε4 carriers have greater levels of tau tangles in memory centers, even after controlling for amyloid plaques. The study provides evidence that the gene's risk of dementia is related to both hallmark pathologies of Alzheimer's disease.
Researchers at Universidad Complutense de Madrid have identified brain biomarkers for detecting Alzheimer's disease. A study found that patients with Mild Cognitive Impairment who develop dementia show increased and then decreased synchronization in brain regions, indicating cortical network dysfunction.
Researchers at Baylor College of Medicine report no link between increased levels of herpes virus and Alzheimer's disease, contrary to a previous study. The team also provides a new statistical and computational framework for analyzing large-scale sequencing data.
Researchers have found that suppressing MSUT2, a gene involved in tau regulation, may protect against Alzheimer's disease. The study also highlights the importance of preserving PABPN1 activity to prevent brain degeneration.
A study by University of Alberta chemists identifies CD33 protein as a factor that may decrease the likelihood of Alzheimer's disease. The most common type of CD33 protein plays a crucial role in modulating microglia function, which can protect against neurodegenerative plaques.
Researchers found that two identical triplets who shared the same DNA developed Alzheimer's at different ages, suggesting other factors contribute to its development. The study also discovered that environmental and lifestyle factors can affect an individual's biological age and potentially delay or accelerate dementia onset.
Researchers at Stanford University School of Medicine found a common mutation in the ALDH2 enzyme may contribute to Alzheimer's disease, increasing cell damage from alcohol metabolism. The mutation, prevalent in East Asian populations, causes reduced enzyme activity and buildup of toxic acetaldehyde.
Researchers at the University of Edinburgh found that amyloid beta and tau proteins work together to hamper key genes responsible for brain messaging in people with Alzheimer's disease. This damage can be reversed by reducing the presence of tau proteins, according to the study.
A phase-one clinical trial will test the safety and tolerability of emtricitabine in 35 patients with Alzheimer's, while evaluating its effect on inflammation markers. The trial aims to determine if the drug may benefit people with Alzheimer's by reducing age-related cellular inflammation.
Ruth-Universität Bochum researcher receives ERC grant to study grid cell patterns in human brain, potential link to Alzheimer's disease. The research aims to better understand the role of grid cells in spatial navigation and identify early markers for Alzheimer's.
A ketone-supplemented diet has been shown to restore protective protein levels and decrease mortality rates in mice with Alzheimer's disease. By consuming a diet rich in ketones, the mice experienced fewer seizures and were less likely to die, suggesting that this intervention may help protect interneurons from damage.
The 2020 Edith and Peter O'Donnell Awards recognize Texas researchers making groundbreaking discoveries in Alzheimer's disease treatment, malaria treatment, kidney stone research, and star merger processes. The awards celebrate innovative work that advances science and improves lives.
Researchers aim to understand the needs and experiences of LGBT older adults with Alzheimer's disease and their surrogate decision makers. They will explore emotional, spiritual, and religious aspects of surrogacy and its impact on medical decisions.
Dr. Frost's team identified targets that can mitigate the spread of toxic proteins in the brain, aiming to intervene at the earliest stages of the disease. By preventing tau protein activation, her research holds promise for preventing memory loss and cognitive decline in Alzheimer's patients.
Alzheimer's disease incidence in the US has been declining since 2007, according to a recent analysis. The study found significant geographic variation in incidence rates across the country, with highest rates in the Midwest and South.
Researchers used focused ultrasound to target and open areas of the blood-brain barrier in three women with early-stage Alzheimer's disease. The technique successfully opened and closed the barrier within 24 hours, with no adverse effects.
Researchers at the University of Pittsburgh are using advanced MRI technology to study the connection between small vessel disease and Alzheimer's disease, aiming to identify new prevention and treatment targets. The team will visualize cerebrospinal fluid flow in real-time, shedding light on pathways linking SVD and CSF clearance.
A study by Duke-NUS Medical School researchers has uncovered new insights into how individual cell types in the brain contribute to Alzheimer's disease progression. The study found distinct gene expression profiles and networks across different cell types, providing potential druggable targets for future drug development.
Researchers at Tel Aviv University have discovered a significant overlap between genetic mutations causing autism and those related to Alzheimer's disease. The study found thousands of mutations in the aging brains of Alzheimer's patients, including those affecting the protein ADNP.
A study published in Journal of Alzheimer's Disease shows that a small molecule drug inhibits tau self-association and blocks neurotoxic tau oligomers in an animal model. The compound reduces insoluble tau aggregates and decreases misfolded tau accumulation, demonstrating promising results for treating Alzheimer's disease.
A Monash University study has made key discoveries into the role of gene expression in individual cell types of the brain, contributing to Alzheimer's disease. The research highlights the importance of understanding non-neuronal cells in treating this devastating condition.
A study analyzing data from four types of mouse Alzheimer's models found consistent changes in cell number and gene expression throughout the disease stages. The research provides new targets for intervention and therapy, highlighting the immune system's involvement in early stages of Alzheimer's.
A new study by Temple University Health System scientists shows that extra virgin olive oil (EVOO) can defend against tauopathies, a type of mental decline linked to frontotemporal dementia. EVOO supplementation in mice with abnormal tau protein resulted in a 60% reduction in damaging deposits and improved brain function.
Researchers at Beth Israel Deaconess Medical Center identified a gene variant linked to increased risk of postoperative delirium in older adults. The study suggests that anti-inflammatory treatments may be effective in preventing or mitigating delirium, particularly in patients with the APOE ?4 gene variant.
A new study has identified a genetic variation in the Mucin 6 gene that may contribute to late-onset Alzheimer disease. The findings suggest a strong association between the genetic variant and the disease, implying a large effect size and opening up possibilities for future therapeutic targets.
A nationwide study published in Brain found that higher exposure to fine particle pollution, or PM 2.5, was associated with greater declines in memory performance and more Alzheimer's-like brain changes in older women. The researchers used data from 998 women aged 73-87 and adjusted for other factors.
A new study by Gladstone Institutes reveals that specific patterns of brain activity can predict Alzheimer's symptoms in young mice. By analyzing sharp-wave ripples and short gamma power, researchers found that deficits in these activities at an early age can predict memory problems decades later.
A recent study by the University of California, Davis Health, found that nearly 10% of middle-age and older Latinos in the US meet the criteria for mild cognitive impairment. Factors such as cardiovascular disease and depression were identified as risk factors for MCI.
Researchers are studying brain aging and dementia in 500 individuals born in 1946, using detailed assessments and brain scans to identify risk factors. The goal is to develop better preventative health strategies and improve clinical trials.
The Alzheimer's Association has received a $1.34 million dollar grant from the National Institutes of Health to strengthen psychosocial research in dementia care. The LINC-AD project aims to develop evidence-based measures and tools to improve quality of life for people with dementia and their caregivers.
Researchers developed a retinal hyperspectral imaging technique to detect early signs of Alzheimer's disease. The test scans the retina for biochemical changes associated with the disease, potentially identifying high-risk individuals and facilitating interventions.
Researchers at LSU Health New Orleans School of Medicine have discovered a new mechanism by which elovanoids may protect brain and retinal cells against neurodegenerative diseases. The study identifies elovanoids as a potential therapeutic approach for age-related macular degeneration and Alzheimer's disease.
A new study by RAND Corporation outlines the challenges Australia faces in preparing for a possible breakthrough treatment for Alzheimer's disease. The Australian healthcare system lacks sufficient medical specialists, diagnostic scanners, and infusion centers to handle the influx of patients, leading to long wait times and potential u...
Researchers found that a key Alzheimer's gene (APOE) behaves differently among Caribbean Hispanics depending on ancestral origin. Individuals with African-derived APOE had a 39% lower risk of Alzheimer's compared to those with European-derived APOE.
Researchers found rapamycin modifies blood flow and cognitive decline with aging. The study provides evidence that TOR drives loss of synapses and cerebral blood flow during aging.
A new study identified a gene variant that may delay or prevent Alzheimer's disease. Carrying two copies of the APOE3ch variant may limit tau pathology and neurodegeneration, allowing individuals to age with fewer cognitive impairments. Researchers hope this finding can lead to new treatment strategies for Alzheimer's disease.
Researchers discovered that DAPPD promotes phagocytosis of microglia cells, leading to reduced amyloid deposition and improved cognitive function. The study suggests that targeting neuroinflammation may be a viable therapeutic strategy for neurodegenerative diseases.
Researchers found that serum flotillin levels significantly decrease in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD compared to non-AD controls. Flotillin levels are also negatively associated with brain amyloid deposition, indicating its potential as a blood biomarker for early AD diagnosis.
A rare gene variant, APOE3ch, has been identified as a potential protective factor against Alzheimer's disease. The study, funded by the NIH, reveals that an individual carrying this variant remained dementia-free for nearly three decades beyond expected onset age.
The Alzheimer's Association is investing in three research projects to develop new treatments and protect against Alzheimer's disease. Researchers are exploring a gene that may reduce risk, preventing nerve cell death, and using ultrasound to stimulate brain activity for improved memory.
A new three-year project aims to test the impact of sleep, exercise and low levels of alcohol on the glymphatic system, a recently discovered pathway that removes waste products from the brain. The study may lead to treatments that can target an important cause of both Parkinson's and Alzheimer's.
Researchers at Massachusetts General Hospital have discovered a link between the brain's extracellular matrix and Alzheimer's disease, finding that elastin-like polypeptides increase amyloid-beta peptide accumulation in cell and animal models. This discovery offers new insights into the pathogenesis of Alzheimer's disease.
A new study found that higher education may protect against cognitive decline in older non-Hispanic black people with the APOE e4 gene, a major genetic risk factor for late-onset Alzheimer's disease. The study showed that individuals with more than a high school degree performed similarly to non-carriers on memory tests.
Researchers at Mayo Clinic identified distinct patterns of brain damage associated with different Alzheimer's subtypes and age of onset. These findings suggest that available therapies will be most effective for patients with the hippocampal-sparing subtype and young-onset form of the disease.
A new study found that performing well on two brief tests measuring cognitive ability and odor identification indicates very low risk for Alzheimer's. The tests may offer an accurate way to distinguish between those at risk for Alzheimer's and those with ordinary age-related memory decline.
Research in mouse neurons reveals that misfolded tau protein can quickly spread between neurons without being immediately harmful. Early therapeutic intervention targeting the initial accumulation of tau may halt Alzheimer's disease progression.
A new study shows that nearly all adults with Down syndrome harbor signs of dementia by age 40, and by age 55, three in five will be diagnosed with Alzheimer's disease or a similar neurodegenerative condition. The study highlights the need for early diagnosis and support services for people with Down syndrome as they age.